Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trabodenoson. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 known ✓ | P30542 | 10/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 5/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 4/20 | 1.00 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.73 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.72 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.72 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | TP53 | P04637 | 1/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trabodenoson SCHEMBL15183438 | 1.00 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BTAS1R3 | |
| Trabodenoson SCHEMBL121828 | 1.00 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BTAS1R3 | |
| Trabodenoson SCHEMBL29359454 | 1.00 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BTAS1R3 | |
| Trabodenoson SCHEMBL17513019 | 1.00 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BTAS1R3 | |
| SCHEMBL124574 | 0.99 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BTAS1R3 | |
| SCHEMBL121829 | 0.93 | ADORA1 (0.86) | ADORA1ADORA3ADORA2AADORA2BTAS1R3 | |
| SCHEMBL2488256 | 0.93 | ADORA1 (0.86) | ADORA1ADORA3ADORA2AADORA2BTAS1R3 | |
| SCHEMBL124575 | 0.92 | ADORA1 (0.87) | ADORA1ADORA3ADORA2AADORA2BTAS1R3 | |
| SCHEMBL17207180 | 0.92 | ADORA1 (0.85) | ADORA1ADORA3ADORA2AADORA2BTAS1R3 | |
| SCHEMBL6745875 | 0.91 | ADORA1 (0.82) | ADORA1ADORA3ADORA2AADORA2BTAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013049725-A2 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | TUFTS UNIVERSITY (US) | 2013-04-04 | — | — | WO | claimed |
| US-20140241990-A1 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | TUFTS UNIVERSITY (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2013049725-A2 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | TUFTS UNIVERSITY (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140241990-A1 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | ADORA2A, ADORA1, ADORA3 | ADORA1 2/4885ADORA3 3/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.